Evidence map›Paper›PMID 40038887›Full record

ArticleAlimentary pharmacology & therapeutics2025

Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study.

Nicolas Richard, Aurélien Amiot, Philippe Seksik, Romain Altwegg, David Laharie, Lucine Vuitton, Maria Nachury, Guillaume Bouguen, Stéphane Nancey, Cyrielle Gilletta and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Upadacitinib-Induced Sepsis Resulting in Death in Crohn's Disease: The First Reported Case.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nicolas RichardDepartment of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.
Aurélien AmiotDepartment of Gastroenterology, Hopitaux Universitaires Bicêtre, AP-HP, Université Paris Saclay, INSERM CESP, Le Kremlin Bicêtre, France.
Philippe SeksikDepartment of Gastroenterology, CRSA, Sorbonne Université, INSERM, APHP, Hôpital Saint-Antoine, Paris, France.
Romain AltweggDepartment of Gastroenterology, CHU of Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0003-4618-7942
David LaharieCHU de Bordeaux, Centre Medico-Chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology Department, Université de Bordeaux; INSERM CIC 1401, Bordeaux, France.ORCID https://orcid.org/0000-0002-4753-6676
Lucine VuittonDepartment of Gastroenterology, UMR 1098, University of Franche-Comté, Besançon, France.ORCID https://orcid.org/0000-0001-9845-6572
Maria NachuryUniv. Lille, Inserm, CHU Lille, U1286, INFINITE, Institute for Translational Research in Inflammation, Lille, France.
Guillaume BouguenCHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), Rennes, France.ORCID https://orcid.org/0000-0002-7444-5905
Stéphane NanceyDepartment of Gastroenterology, Lyon-Sud Hospital, CHU of Lyon, and INSERM U1111, CIRI, Lyon, France.
Cyrielle GillettaDepartment of Gastroenterology and Pancreatology, CHU of Toulouse RANGUEIL, Toulouse, France.
Cléa RouilonDepartment of Gastroenterology, Caen University Hospital, Caen, France.
Benoît CoffinDepartment of Gastroenterology, AP-HP Nord, Hôpital Louis Mourier, Colombes, France.
Matthieu AllezGastroenterology Department, Hôpital Saint-Louis, APHP, Université Paris Cité, INSERM U1160, Paris, France.ORCID https://orcid.org/0000-0002-2012-7522
Anthony BuissonUniversité Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
Catherine Le BerreHépato-Gastro-Entérologie et Assistance Nutritionnelle, Inserm CIC 1413, Inserm UMR 1235, Institut des Maladies de l'Appareil Digestif (IMAD), Nantes Université, CHU Nantes, Nantes, France.
Mathieu UzzanGastroenterology Department, Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
Ludovic CailloGastroenterology Department, Universitary Hospital of Nîmes, Nîmes, France.
Anne-Laure PelletierGastroenterology Department Bichat-Claude Bernard University Hospital, APHP, Paris, France.
Laurent Peyrin-BirouletDepartment of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France.ORCID https://orcid.org/0000-0003-2536-6618
Mathurin FumeryDepartment of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France.
GETAID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear.

aimsThis study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world cohort.

methodsFrom September 2022 to June 2024, all consecutive patients with refractory luminal CD treated with once daily upadacitinib 45 mg in 29 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (SFCR) at week 12, defined as a Harvey-Bradshaw Index (HBI) of < 4. Clinical response (decrease of ≥ 3 points in HBI and/or HBI < 4), clinical remission, biomarker remission, endoscopic and/or radiologic response and safety were also assessed.

resultsAmong the 223 patients included, all were previously exposed to at least one biologic (median 4, IQR [3, 4]) and 119 (53.8%) had prior intestinal resection. At week 12, SFCR was achieved in 107/197 (54%), clinical response in 129/197 (65%) and clinical remission in 111/197 (56%). A total of, 90 out of 173 (52%) achieved biomarker remission. Endoscopic and/or radiologic response was observed in 18/38 (47%) patients. Clinical response of extraintestinal manifestations was observed in 37/47 (79%) patients and clinical remission in 29/47 (62%). A total of, 65 adverse events (AEs) occurred in 58 patients (26%), including 17 serious AEs, 16 disease exacerbation and one case of colonic EBV-associated lymphoproliferative disorder. Acne was reported in 24/223 (11%) patients.

conclusionIn this real-world cohort of highly refractory CD patients, upadacitinib induction resulted in a clinical response in about two-thirds of patients and in SFCR in half of the patients, with an acceptable safety profile.

Indexed as

Crohn DiseaseHeterocyclic Compounds, 3-RingAdultCohort StudiesFemaleFranceHumansMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeYoung AdultHeterocyclic Compounds, 3-RingupadacitinibCrohn's diseasereal‐world evidenceupadacitinib

Identifiers

PMID40038887
PMCPMC12013792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.